In Vivo Safety, Biodistribution and Antitumor Effects of uPAR Retargeted Oncolytic Measles Virus in Syngeneic Cancer Models

The urokinase receptor (uPAR) is a clinically relevant target for novel biological therapies. We have previously rescued oncolytic measles viruses fully retargeted against human (MV-h-uPA) or murine (MV-m-uPA) uPAR. Here, we investigated the in vivo effects of systemic administration of MV-m-uPA in...

Descripción completa

Detalles Bibliográficos
Autores principales: Jing, Yuqi, Zaias, Julia, Duncan, Robert, Russell, Stephen J., Merchan, Jaime R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3949200/
https://www.ncbi.nlm.nih.gov/pubmed/24430235
http://dx.doi.org/10.1038/gt.2013.84

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3949200/
https://www.ncbi.nlm.nih.gov/pubmed/24430235
http://dx.doi.org/10.1038/gt.2013.84

Ejemplares similares